Emerging Markets Earnings Roundup: AbbVie (Part 5)
This article was originally published in PharmAsia News
Executive Summary
AbbVie was required to stay largely mum on its second quarter earnings call as it complies with the UK Takeover Code in its deal with Shire. But some numbers on Humira were released for international sales that show the franchise growing well outside of the U.S.
You may also be interested in...
Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology
While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.